Fig. 8: Silencing of miR-9-5p attenuated 25-HC-mediated tumor metastasis.

a Schematic diagram of antagomir treated mouse model. 231/Luc cells injected at day 0 in NSG mice. On day 14, tumor was detected. At day 28, mice were treated with antagomir (10 nmol) every 3 days untiled euthanized. 4T1/Luc cells injected at day 0 in BALB/c mice. On day 8, tumor was detected. At day 25, mice were treated with antagomir (10 nmol) every 3 days untiled euthanized, during which time the tumor was removed on day 28. b RT-qPCR-determined miR-9-5p levels in serum, tumor, liver and lung in 231/Luc cells xenografted mice treated with indicated antagomir and with 231/Ctrl, 231/Rab27a KD and 231/miR-9 KO mice (one-way ANOVA, n = 5 mice per group). c Representative PET/CT imaging with ¹⁸F-FDG for accessing liver and lung uptake and quantification in 4T1/Luc cells xenografted mice treated with indicated antagomir. d Representative bioluminescence images of metastasis site in liver and lung of xenografted mice treated with indicated antagomir and with 231/Ctrl, 231/Rab27a KD and 231/miR-9 KO mice. e Quantification of liver and lung metastasis of xenografted mice treated with indicated antagomir and with 231/Ctrl, 231/Rab27a KD and 231/miR-9 KO mice (one-way ANOVA, n = 5 mice per group). f Quantification of gene expression in liver from xenografted mice treated with indicated antagomir and with 231/Ctrl, 231/Rab27a KD and 231/miR-9 KO mice (one-way ANOVA, n = 5 mice per group). g Quantification of gene expression in liver from xenografted mice (one-way ANOVA, n = 5 mice per group). h Immunoblotting analysis of liver sample collected from xenografted mice treated with indicated antagomir and with 231/Ctrl, 231/Rab27a KD and 231/miR-9 KO mice. Data are presented as mean ± s.d. Source data and exact P value are provided as a Source data file.